Karolinska Developments portföljbolag SVF Vaccines presenterar positiva data från en fas 1-studie med bolagets universella vaccin mot covid-19
October 21, 2024 07:43 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE, 21 oktober 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat positiva kliniska säkerhets- och...
Karolinska Development’s portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine
October 21, 2024 07:43 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, October 21, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, has presented positive clinical safety and immunogenicity...
Karolinska Developments portföljbolag Umecrine Cognition presenterar nya prekliniska Parkinsondata för golexanolon på den vetenskapliga konferensen INBC 2024
October 17, 2024 02:50 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE, 17 oktober 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition kommer att presentera nya prekliniska data för golexanolon som...
Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024
October 17, 2024 02:50 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present new preclinical data on...
Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma
October 15, 2024 06:10 ET
|
Karolinska Development AB (publ)
Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till extra bolagsstämma onsdagen den 13 november 2024 kl. 11.00 hos Cirio...
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
October 15, 2024 06:10 ET
|
Karolinska Development AB (publ)
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Wednesday, November...
Karolinska Development avyttrar hela innehavet i det danska dermatologibolaget Henlez
September 23, 2024 10:26 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 23 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolaget säljer samtliga aktier i portföljbolaget Henlez ApS. Efter avyttringen består Karolinska...
Karolinska Development divests its holding in the Danish dermatology company Henlez
September 23, 2024 10:26 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS. Following the transaction,...
Karolinska Developments portföljbolag AnaCardio rapporterar framsteg i två kliniska studier av läkemedelskandidaten AC01
September 17, 2024 02:35 ET
|
Karolinska Development AB (publ)
STOCKHOLM, 17 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört den kliniska studien AC01-FE som genomförts i USA parallellt...
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
September 17, 2024 02:35 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also...